{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+Neuroendocrine&page=4", "query": { "condition": "Carcinoma Neuroendocrine", "page": 4 }, "page_size": 10 }, "pagination": { "page": 4, "page_size": 10, "total_count": 946, "total_pages": 95, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+Neuroendocrine&page=5&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Carcinoma+Neuroendocrine&page=3&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-09T23:37:11.407Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT05557045", "title": "A Study of JZP815 Oral Capsules in Adult Participants With Advanced or Metastatic Solid Tumors Harboring Mitogen Activated Protein Kinase (MAPK) Pathway Alterations to Investigate the Safety, Dosing, and Antitumor Activity of JZP815", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancer", "Metastatic Cancer", "Solid Tumor", "Melanoma", "Non-small Cell Lung Cancer (NSCLC)", "Colorectal Cancer (CRC)", "Anaplastic Thyroid Cancer (ATC)" ], "interventions": [ { "name": "JZP815", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Jazz Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 98, "start_date": "2022-10-10", "completion_date": "2028-04-01", "has_results": false, "last_update_posted_date": "2026-09-10", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 15, "location_summary": "Los Angeles, California • Denver, Colorado • Orlando, Florida + 10 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "Denver", "state": "Colorado" }, { "city": "Orlando", "state": "Florida" }, { "city": "Sarasota", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT05557045" }, { "nct_id": "NCT06008977", "title": "Exercise to Boost Response to Checkpoint Blockade Immunotherapy", "overall_status": "ACTIVE_NOT_RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "NA" ], "conditions": [ "Cutaneous Melanoma", "Cutaneous Squamous Cell Carcinoma", "Merkel Cell Carcinoma" ], "interventions": [ { "name": "Exercise Test", "type": "OTHER" } ], "intervention_types": [ "OTHER" ], "sponsor": "AdventHealth Translational Research Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 12, "start_date": "2024-06-03", "completion_date": "2026-12", "has_results": false, "last_update_posted_date": "2026-03-25", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 1, "location_summary": "Orlando, Florida", "locations": [ { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT06008977" }, { "nct_id": "NCT01183663", "title": "Lenalidomide in Combination With Bevacizumab, Sorafenib, Temsirolimus, or 5-Fluorouracil, Leucovorin, Oxaliplatin (FOLFOX)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Cancers" ], "interventions": [ { "name": "Lenalidomide", "type": "DRUG" }, { "name": "Bevacizumab", "type": "DRUG" }, { "name": "Sorafenib", "type": "DRUG" }, { "name": "Temsirolimus", "type": "DRUG" }, { "name": "Oxaliplatin", "type": "DRUG" }, { "name": "Leucovorin", "type": "DRUG" }, { "name": "5-fluorouracil", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "M.D. Anderson Cancer Center", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 180, "start_date": "2010-08", "completion_date": "2016-05", "has_results": false, "last_update_posted_date": "2016-06-03", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT01183663" }, { "nct_id": "NCT00655655", "title": "Everolimus and Vatalanib in Treating Patients With Advanced Solid Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Gastrinoma", "Glucagonoma", "Insulinoma", "Metastatic Gastrointestinal Carcinoid Tumor", "Metastatic Pheochromocytoma", "Pancreatic Polypeptide Tumor", "Recurrent Gastrointestinal Carcinoid Tumor", "Recurrent Islet Cell Carcinoma", "Recurrent Melanoma", "Recurrent Neuroendocrine Carcinoma of the Skin", "Recurrent Non-small Cell Lung Cancer", "Recurrent Pheochromocytoma", "Recurrent Renal Cell Cancer", "Somatostatinoma", "Stage III Neuroendocrine Carcinoma of the Skin", "Stage IV Melanoma", "Stage IV Non-small Cell Lung Cancer", "Stage IV Renal Cell Cancer", "Thyroid Gland Medullary Carcinoma", "Unspecified Adult Solid Tumor, Protocol Specific" ], "interventions": [ { "name": "everolimus", "type": "DRUG" }, { "name": "vatalanib", "type": "DRUG" }, { "name": "pharmacological study", "type": "OTHER" }, { "name": "laboratory biomarker analysis", "type": "OTHER" }, { "name": "dynamic contrast-enhanced magnetic resonance imaging", "type": "PROCEDURE" }, { "name": "ultrasound imaging", "type": "PROCEDURE" } ], "intervention_types": [ "DRUG", "OTHER", "PROCEDURE" ], "sponsor": "Mayo Clinic", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 96, "start_date": "2004-12", "completion_date": "2018-01-11", "has_results": false, "last_update_posted_date": "2024-08-21", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 1, "location_summary": "Rochester, Minnesota", "locations": [ { "city": "Rochester", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT00655655" }, { "nct_id": "NCT01391143", "title": "Safety Study of MGA271 in Refractory Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Prostate Cancer", "Melanoma", "Renal Cell Carcinoma", "Triple-negative Breast Cancer", "Head and Neck Cancer", "Bladder Cancer", "Non-small Cell Lung Cancer" ], "interventions": [ { "name": "MGA271", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "MacroGenics", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 179, "start_date": "2011-07", "completion_date": "2019-04-18", "has_results": false, "last_update_posted_date": "2022-02-08", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 12, "location_summary": "Los Angeles, California • New Haven, Connecticut • Tampa, Florida + 7 more", "locations": [ { "city": "Los Angeles", "state": "California" }, { "city": "New Haven", "state": "Connecticut" }, { "city": "Tampa", "state": "Florida" }, { "city": "Chicago", "state": "Illinois" }, { "city": "Louisville", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT01391143" }, { "nct_id": "NCT01024387", "title": "AMG 479 in Advanced Carcinoid and Pancreatic Neuroendocrine Tumors", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Tumor", "Carcinoid Tumor", "Pancreatic Neuroendocrine Tumor" ], "interventions": [ { "name": "AMG 479", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Dana-Farber Cancer Institute", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 60, "start_date": "2010-03", "completion_date": "2017-01", "has_results": true, "last_update_posted_date": "2018-03-08", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 3, "location_summary": "Tampa, Florida • Boston, Massachusetts", "locations": [ { "city": "Tampa", "state": "Florida" }, { "city": "Boston", "state": "Massachusetts" }, { "city": "Boston", "state": "Massachusetts" } ], "official_url": "https://clinicaltrials.gov/study/NCT01024387" }, { "nct_id": "NCT05144698", "title": "RAPA-201 Therapy of Solid Tumors", "overall_status": "RECRUITING", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1", "PHASE2" ], "conditions": [ "Solid Tumor", "Small Cell and Non-small Cell Lung Cancer", "Head and Neck Cancer", "Squamous Cell Carcinoma of Oral Cavity", "Squamous Cell Carcinoma of Larynx", "Squamous Cell Carcinoma of Nasopharynx", "Squamous Cell Carcinoma of Other Specified Sites of Skin", "Malignant Melanoma", "Esophageal Squamous Cell Carcinoma" ], "interventions": [ { "name": "RAPA-201 Rapamycin Resistant T Cells", "type": "BIOLOGICAL" }, { "name": "Chemotherapy Prior to RAPA-201 Therapy", "type": "DRUG" }, { "name": "Pembrolizumab (PD-1 Blocking Antibody)", "type": "DRUG" } ], "intervention_types": [ "BIOLOGICAL", "DRUG" ], "sponsor": "Rapa Therapeutics LLC", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 37, "start_date": "2021-08-01", "completion_date": "2026-12-31", "has_results": false, "last_update_posted_date": "2025-05-14", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 1, "location_summary": "Hackensack, New Jersey", "locations": [ { "city": "Hackensack", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT05144698" }, { "nct_id": "NCT00026533", "title": "Thalidomide in Treating Patients With Thyroid Cancer", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Head and Neck Cancer" ], "interventions": [ { "name": "thalidomide", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Kenneth Ain", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": null, "start_date": "2001-06", "completion_date": "2005-12", "has_results": false, "last_update_posted_date": "2017-06-06", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 1, "location_summary": "Lexington, Kentucky", "locations": [ { "city": "Lexington", "state": "Kentucky" } ], "official_url": "https://clinicaltrials.gov/study/NCT00026533" }, { "nct_id": "NCT03901378", "title": "Pembrolizumab With Chemotherapy in Metastatic or Unresectable High Grade Gastroenteropancreatic or Lung Neuroendocrine Carcinoma", "overall_status": "WITHDRAWN", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Neuroendocrine Carcinoma", "Large Cell Neuroendocrine Carcinoma of the Lung", "High Grade Neuroendocrine Carcinoma, Any Site" ], "interventions": [ { "name": "Pembrolizumab", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ochsner Health System", "sponsor_class": "OTHER", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 0, "start_date": "2019-10-02", "completion_date": "2021-01-21", "has_results": false, "last_update_posted_date": "2021-01-25", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 2, "location_summary": "Kenner, Louisiana • New Orleans, Louisiana", "locations": [ { "city": "Kenner", "state": "Louisiana" }, { "city": "New Orleans", "state": "Louisiana" } ], "official_url": "https://clinicaltrials.gov/study/NCT03901378" }, { "nct_id": "NCT02159989", "title": "Sapanisertib and Ziv-Aflibercept in Treating Patients With Recurrent Solid Tumors That Are Metastatic or Cannot Be Removed by Surgery", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Advanced Malignant Solid Neoplasm", "Fibrolamellar Carcinoma", "Metastatic Malignant Solid Neoplasm", "Ovarian Carcinoma", "Pancreatic Neuroendocrine Tumor", "Recurrent Malignant Solid Neoplasm", "Refractory Malignant Solid Neoplasm", "Unresectable Solid Neoplasm" ], "interventions": [ { "name": "Sapanisertib", "type": "DRUG" }, { "name": "Ziv-Aflibercept", "type": "BIOLOGICAL" } ], "intervention_types": [ "DRUG", "BIOLOGICAL" ], "sponsor": "National Cancer Institute (NCI)", "sponsor_class": "NIH", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 83, "start_date": "2014-06-18", "completion_date": "2024-01-29", "has_results": true, "last_update_posted_date": "2025-10-20", "last_synced_at": "2026-10-09T23:37:11.407Z", "location_count": 1, "location_summary": "Houston, Texas", "locations": [ { "city": "Houston", "state": "Texas" } ], "official_url": "https://clinicaltrials.gov/study/NCT02159989" } ] }